Analysis of the efficacy and mechanism of everolimus/Afinitor

Everolimus is an oral targeted drug that belongs to the mammalian target of rapamycin (mTOR) inhibitor class. It exhibits a unique mechanism of action in the treatment of a variety of malignant tumors and immune-related diseases by precisely blocking key signaling pathways for cell growth and metabolism. The core target of everolimus is mTOR protein complex 1 (mTORC1), a signaling pathway that plays a key regulatory role in cell proliferation, metabolism and angiogenesis. Cancer cells often overactivate the mTOR pathway to evade apoptosis and promote tumor growth. Everolimus inhibits mTORC1, thereby effectively blocking the energy supply and protein synthesis of tumor cells to achieve anti-tumor effects.

Clinically, everolimus is widely used to treat a variety of advanced cancers, such as renal cell carcinoma, breast cancer, pancreatic neuroendocrine tumors (PNET), etc., and has also shown efficacy in some rare diseases such as tuberous sclerosis-related tumors. Unlike traditional chemotherapy drugs, everolimus does not directly kill cancer cells, but inhibits tumor growth signals through "starvation therapy", thereby reducing tumor metabolic activity. This mechanism makes its toxicity more controllable and its side effects relatively mild.

In terms of pharmacological characteristics, everolimus is well absorbed after oral administration, can be rapidly distributed into tissues and stably acts on themTOR pathway. Its metabolism is mainly completed through the CYP3A4 enzyme system, so the interaction with other drugs needs to be paid attention to. Foreign studies have shown that everolimus can also reduce the expression of angiogenic factors by affecting the tumor microenvironment, thereby cutting off the "nutrient supply chain" of cancer cells and further enhancing the anti-tumor effect. At the same time, it also has an immunomodulatory effect and is used to prevent rejection after organ transplantation. This "dual mechanism" makes it have broad application prospects in multiple medical fields.

Reference materials:https://www.drugs.com/everolimus.html